Detalhe da pesquisa
1.
Incorporating patient-reported outcome data into a predictive calculator for allogeneic hematopoietic cell transplantation recipients.
Cancer
; 130(10): 1826-1835, 2024 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38198511
2.
Symptom clusters and their impact on quality of life in multiple myeloma survivors: Secondary analysis of BMT CTN 0702 trial.
Br J Haematol
; 204(4): 1429-1438, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38348544
3.
Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation.
Br J Haematol
; 204(3): 887-891, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38054558
4.
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Haematologica
; 109(3): 906-914, 2024 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37646658
5.
Development and initial validation of the AL-PROfile patient-reported outcome measure in light chain (AL) amyloidosis.
Eur J Haematol
; 112(6): 900-909, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38350661
6.
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Cancer
; 129(14): 2179-2191, 2023 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37021929
7.
Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
Br J Haematol
; 203(5): 736-746, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37287117
8.
Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study.
Haematologica
; 108(12): 3384-3391, 2023 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37439357
9.
Differences in patient-reported outcomes (PROs) by disease severity in light chain (AL) amyloidosis.
Eur J Haematol
; 111(4): 536-543, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37401100
10.
Health-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102.
Am J Hematol
; 98(2): 229-250, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36251401
11.
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma.
Am J Hematol
; 98(1): 140-147, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35567778
12.
A cross-sectional study of patient-reported outcomes and symptom burden using PROMIS and PRO-CTCAE measures in light chain amyloidosis.
Qual Life Res
; 32(6): 1807-1817, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-36738402
13.
Important questions for the malignant hematologist to consider when designing or evaluating a study with patient-reported outcome measures (PROMs).
Eur J Haematol
; 109(1): 3-9, 2022 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-35403753
14.
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy.
Am J Hematol
; 97(9): 1170-1177, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35731911
15.
Exploring health behaviors and the feasibility of a lifestyle intervention for patients with multiple myeloma.
Support Care Cancer
; 30(12): 9771-9779, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36287278
16.
Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study.
Qual Life Res
; 31(4): 1083-1092, 2022 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-34255276
17.
Rap1A, Rap1B, and ß-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol.
Yale J Biol Med
; 95(1): 45-56, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-35370486
18.
Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older.
Cancer
; 127(22): 4233-4239, 2021 11 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34374445
19.
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.
Cancer
; 127(1): 82-92, 2021 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32966625
20.
Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma.
Biol Blood Marrow Transplant
; 26(12): 2229-2236, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32920204